Henning Baldauf

External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails

Johannes Schetelig, Henning Baldauf, Falk Heidenreich et al. · Blood · 2020 · 55 citations · Full text

Medicine, Hematology, Molecular Biology +13

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

Matthias Stelljes, Jan Moritz Middeke, Gesine Bug et al. · The Lancet Haematology · 2024 · 49 citations · Full text

Medicine, Hematology, Oncology +15

In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Matthias Stelljes, Jan Moritz Middeke, Gesine Bug et al. · Blood · 2022 · 42 citations

Medicine, Oncology, Chemotherapy +12

CCR5Δ32 mutations do not determine COVID-19 disease course

Stefanie N. Bernas, Henning Baldauf, Sarah Wendler et al. · International Journal of Infectious Diseases · 2021 · 25 citations · Full text

Life Sciences, Genetics, Infectious Diseases +15

Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia

Johannes Schetelig, Henning Baldauf, Linda Köster et al. · Frontiers in Immunology · 2021 · 24 citations · Full text

Medicine, Hematology, Immunology +17